scPharmaceuticals (SCPH)
(Delayed Data from NSDQ)
$4.04 USD
-0.71 (-14.95%)
Updated May 20, 2024 04:00 PM ET
After-Market: $4.04 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
SCPH 4.04 -0.71(-14.95%)
Will SCPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SCPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SCPH
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
SCPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for SCPH
Analysts Have Conflicting Sentiments on These Healthcare Companies: scPharmaceuticals (SCPH), Andlauer Healthcare Group (OtherANDHF) and Roche Holding AG (OtherRHHVF)
scPharmaceuticals management to meet with Craig-Hallum
Furoscix Growth Prospects Anchor Buy Rating for scPharmaceuticals
Analysts Are Bullish on These Healthcare Stocks: scPharmaceuticals (SCPH), Optinose (OPTN)
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), scPharmaceuticals (SCPH) and Ascendis Pharma (ASND)